Types of Expectorants
Expectorants are classified into four main categories based on their mechanism of action: expectorants (which increase airway secretion volume), mucolytics (which break down mucus polymers), mucokinetics (which enhance mucus clearance), and mucoregulators (which suppress mucus hypersecretion). 1, 2
Classification System
1. Expectorants (Classic)
These agents theoretically increase airway water or secretion volume to enhance cough effectiveness:
Guaifenesin (Robitussin, Mucinex): The most commonly used over-the-counter expectorant
Hyperosmolar agents (newer approach):
2. Mucolytics
These degrade polymers within secretions to reduce viscosity:
Thiol-containing agents:
- N-acetylcysteine
- Erdosteine
- Important limitation: Classic mucolytics that depolymerize mucin have no proven benefit and carry risk of epithelial damage when administered via aerosol 3
Peptide mucolytics:
3. Mucokinetics
These increase clearance efficiency through cough or mucociliary transport:
- Bronchodilators: Increase cough flow in patients with airway hyperreactivity 2
- Surfactants: Act as abhesives, decreasing mucus attachment to cilia and epithelium - one of the most promising medication classes 3, 2
4. Mucoregulators
These reduce mucus secretion volume, particularly effective in hypersecretory states:
Anticholinergics:
Leukotriene receptor antagonists 6
Dosing and Contraindications
Critical Evidence Gap
The provided evidence does not contain specific dosing recommendations for adults or children, nor detailed contraindication lists. This represents a significant limitation in the literature reviewed.
Pediatric Considerations
Cough medicines should not be used in children, especially young children 7. Over-the-counter cough preparations:
- Lack efficacy evidence
- Can delay serious underlying diagnoses
- Have caused complications and deaths
- Have faced escalating regulatory restrictions worldwide over the past 20 years 7
Clinical Decision Algorithm
When considering expectorant therapy:
First, determine if specific therapy is available for the underlying cause (e.g., bronchodilators for asthma, antibiotics for bacterial infection) - this is always preferred over non-specific expectorant therapy 5
Consider expectorants only when:
- Etiology of cough is unknown
- Specific therapy requires time to become effective
- Specific therapy will be ineffective (e.g., inoperable lung cancer) 5
Match agent to secretion type:
- For thick mucus in proximal airways: Consider mucokinetics or agents favoring cough (thick layer, high viscosity) 4
- For distal airway obstruction: Consider agents favoring mucociliary transport (thin gel layer, low viscosity) 4
- For purulent secretions (CF, severe inflammation): Consider DNA-active agents like dornase alfa 3
For chronic inflammatory airway diseases with hypersecretion: Prioritize mucoregulators (inhaled ipratropium, corticosteroids, macrolides) over classic expectorants 5, 6
Common Pitfalls
- Avoid guaifenesin-dextromethorphan combinations - risk of airway obstruction outweighs unproven benefits 3
- Do not use aerosolized N-acetylcysteine - epithelial damage risk without proven benefit 3
- Recognize that most mucoactive drugs lack well-designed clinical trial evidence supporting their use 4, 2
- Different mechanisms favor different locations: Drugs that help proximal airway clearance may not help distal airways 4